Clinical Trial Update: Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis [Phase 2]

View source ↗

Summary

Phase 2 trial results for Abrilumab (AMG 181) in adults with moderate to severe Ulcerative Colitis have been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Abrilumab (AMG 181)

Snippet

Sponsor: Amgen | Conditions: Ulcerative Colitis | Phase 2 | Status: COMPLETED | Results posted: 2019-06-27